---
schema_version: "secwatch.filing_event.v1"
accession: "0001790340-25-000059"
form_type: "8-K"
ticker: "IMRX"
cik: "0001790340"
company_name: "Immuneering Corp"
filed_at: "2025-05-05T23:59:59+00:00"
generated_at: "2026-05-22T18:07:43.541529+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Immuneering reports Q1 2025 results: net loss $15M, positive IMM-1-104 data, CMO named

## Summary
- Net loss $15.0M ($0.42/sh) vs $14.3M ($0.49/sh) in Q1 2024; R&D expenses $11.5M.
- Cash $35.9M as of March 31, 2025; runway extended into 2026.
- Positive IMM-1-104 data: 13-month monotherapy PFS in third-line pancreatic cancer; complete response in first-line combo with chemo.
- Named Dr. Igor Matushansky as CMO; signed clinical supply agreement with Regeneron for Libtayo combo in NSCLC.

## SEC filing metadata
- accession: 0001790340-25-000059
- form_type: 8-K
- ticker: IMRX
- cik: 0001790340
- company_name: Immuneering Corp
- filed_at: 2025-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1790340/000179034025000059/0001790340-25-000059-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1790340/000179034025000059/imrx-20250505.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001790340-25-000059
- JSON: https://secwatch.observer/filing/0001790340-25-000059.json
- Plain text: https://secwatch.observer/filing/0001790340-25-000059.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.